These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

853 related items for PubMed ID: 19237632

  • 1. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
    Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S.
    J Clin Oncol; 2009 Apr 01; 27(10):1564-71. PubMed ID: 19237632
    [Abstract] [Full Text] [Related]

  • 2. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
    Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S.
    J Clin Oncol; 2007 Oct 01; 25(28):4431-7. PubMed ID: 17785705
    [Abstract] [Full Text] [Related]

  • 3. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    Fizazi K, Bosserman L, Gao G, Skacel T, Markus R.
    J Urol; 2009 Aug 01; 182(2):509-15; discussion 515-6. PubMed ID: 19524963
    [Abstract] [Full Text] [Related]

  • 4. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
    Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman RE, Paterson AH, Gao GM, Kinsey AC, Peterson MC, Jun S.
    Clin Cancer Res; 2008 Oct 15; 14(20):6690-6. PubMed ID: 18927312
    [Abstract] [Full Text] [Related]

  • 5. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    Fizazi K, Bosserman L, Gao G, Skacel T, Markus R.
    J Urol; 2013 Jan 15; 189(1 Suppl):S51-7; discussion S57-8. PubMed ID: 23234632
    [Abstract] [Full Text] [Related]

  • 6. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure.
    Body JJ, Lipton A, Gralow J, Steger GG, Gao G, Yeh H, Fizazi K.
    J Bone Miner Res; 2010 Mar 15; 25(3):440-6. PubMed ID: 19653815
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.
    J Clin Oncol; 2011 Mar 20; 29(9):1125-32. PubMed ID: 21343556
    [Abstract] [Full Text] [Related]

  • 8. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
    Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ.
    Clin Cancer Res; 2006 Feb 15; 12(4):1221-8. PubMed ID: 16489077
    [Abstract] [Full Text] [Related]

  • 9. Denosumab dose selection for patients with bone metastases from solid tumors.
    Doshi S, Sutjandra L, Zheng J, Sohn W, Peterson M, Jang G, Chow AT, Pérez-Ruixo JJ.
    Clin Cancer Res; 2012 May 01; 18(9):2648-57. PubMed ID: 22394983
    [Abstract] [Full Text] [Related]

  • 10. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A, Jacobs I.
    Curr Opin Support Palliat Care; 2011 Sep 01; 5(3):258-64. PubMed ID: 21826000
    [Abstract] [Full Text] [Related]

  • 11. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
    Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A.
    Clin Cancer Res; 2012 Sep 01; 18(17):4841-9. PubMed ID: 22893628
    [Abstract] [Full Text] [Related]

  • 12. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
    Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.
    J Clin Oncol; 2010 Dec 10; 28(35):5132-9. PubMed ID: 21060033
    [Abstract] [Full Text] [Related]

  • 13. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases.
    Yonemori K, Fujiwara Y, Minami H, Kitagawa K, Fujii H, Arai T, Sohn W, Ohkura M, Ohtsu T.
    Cancer Sci; 2008 Jun 10; 99(6):1237-42. PubMed ID: 18429961
    [Abstract] [Full Text] [Related]

  • 14. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
    Tamiya M, Tokunaga S, Okada H, Suzuki H, Kobayashi M, Sasada S, Okamoto N, Morishita N, Matsuura Y, Miyamoto N, Hattori M, Taira K, Daga H, Takeda K, Hirashima T.
    Clin Lung Cancer; 2013 Jul 10; 14(4):364-9. PubMed ID: 23276824
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonates and other bone agents for breast cancer.
    Wong MH, Stockler MR, Pavlakis N.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD003474. PubMed ID: 22336790
    [Abstract] [Full Text] [Related]

  • 16. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ, Kaura S.
    J Med Econ; 2012 Feb 15; 15(1):175-84. PubMed ID: 22017235
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.
    J Med Econ; 2012 Feb 15; 15(4):712-23. PubMed ID: 22409231
    [Abstract] [Full Text] [Related]

  • 18. [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].
    Akaza H, Tsukamoto T, Suzuki K, Namiki M, Ozono S, Naitodept S.
    Gan To Kagaku Ryoho; 2012 Feb 15; 39(2):207-12. PubMed ID: 22333629
    [Abstract] [Full Text] [Related]

  • 19. Denosumab an option for patients with bone metastasis from breast cancer.
    Barton MK.
    CA Cancer J Clin; 2011 Feb 15; 61(3):135-6. PubMed ID: 21532096
    [No Abstract] [Full Text] [Related]

  • 20. New developments for treatment and prevention of bone metastases.
    Body JJ.
    Curr Opin Oncol; 2011 Jul 15; 23(4):338-42. PubMed ID: 21519257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.